Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > BioPub

<< Previous

Bullboard Posts

Next >>

Comment by argeliomon Nov 19, 2020 10:15am

133 Views

Post# 31930174

RE:RE:RE:RE:RE:RE:BioPub

Sorry, try any of the following:

You can Google "Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning" or use one of the following links. Worth reading.

https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6491384&blobtype=pdf

www.researchgate.net/publication/331944554_Discovery_of_therapeutic_agents_for_prostate_cancer_using_genome-scale_metabolic_modeling_and_drug_repositioning

pubmed.ncbi.nlm.nih.gov/30905848/

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland